DOCSLIB.ORG

Lenalidomide (Revlimid) for Mantle Cell Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lenalidomide (Revlimid) for Mantle Cell Lymphoma Horizon Scanning Centre September 2013 Lenalidomide (Revlimid) for mantle cell lymphoma SUMMARY NIHR HSC ID: 4375 Lenalidomide (Revlimid) is intended to be used as therapy for relapsed or refractory mantle cell lymphoma. If licensed, it will provide an additional treatment option for this patient group. Lenalidomide is a small molecule immunomodulatory drug and a structural analogue of thalidomide. It is currently licensed in the EU for multiple myeloma. This briefing is Mantle cell lymphoma is a rare form of non-Hodgkin lymphoma, affecting B based on lymphocytes in the lymph nodes. Diagnosis peaks at around age 65 and the information majority of patients present with advanced disease. The one- and five-year available at the time survival rates are 71% and 27%, respectively. Most patients will respond to of research and a treatment, however mantle cell lymphoma typically progresses and median limited literature survival is around 3 years. search. It is not intended to be a Treatment for mantle cell lymphoma is dependent on stage, grade, definitive statement performance status and whether or not patients are eligible for stem cell or on the safety, bone marrow transplant. There is no standardised care and entry into a efficacy or clinical trial is recommended for eligible patients. Lenalidomide is currently in effectiveness of the phase II clinical trials comparing its effect on progression-free survival health technology against treatment with the investigating clinician’s choice of single agent. covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. NIHR Horizon Scanning Centre, University of Birmingham Email: [email protected] Web: http://www.hsc.nihr.ac.uk NIHR Horizon Scanning Centre TARGET GROUP • Mantle cell lymphoma (MCL): relapsed or refractory. TECHNOLOGY DESCRIPTION Lenalidomide (Revlimid; CC-5013) is a small molecule immunomodulatory drug and a structural analogue of thalidomide. Its mechanism of action is yet to be defined but includes antineoplastic, anti-angiogenic, pro-erythropoietic and immunomodulatory properties1. In clinical trials, lenalidomide was administered orally at 10mg or 25mg, once daily for 21 days of a 28 day cycle2 . Lenalidomide is licensed in the EU for multiple myeloma (in combination with dexamethasone) and myelodysplastic syndromes. Recognised adverse effects (≥10%) include infections, thrombocytopenia, neutropenias, anaemia, haemorrhage, leucopenias, hypokalaemia, decreased appetite, peripheral neuropathies, dizziness, tremor, dysgeusia, headache, blurred vision, venous thromboembolic events, dyspnoea, nasopharyngitis, pharyngitis, bronchitis, epistaxis, constipation, diarrhoea, abdominal pain, nausea, vomiting, rashes, dry skin, pruritus, muscle spasms, bone pain, musculoskeletal and connective tissue pain and discomfort, arthralgia, myalgia, fatigue, oedema, pyrexia and influenza-like illness syndrome3. Lenalidomide is also in phase III clinical trials for: • chronic lymphocytic leukaemia • diffuse large B-cell lymphoma • follicular lymphoma • multiple myeloma • myelodysplastic syndromes • prostate cancer and in phase II trials for: • acute myeloid leukaemia, • T-cell leukaemia-lymphoma • chronic lymphocytic leukaemia • glioblastoma • myelofibrosis • non-Hodgkin’s lymphoma INNOVATION and/or ADVANTAGES If licensed, lenalidomide will provide an additional treatment option for this patient group. DEVELOPER Celgene. 2 NIHR Horizon Scanning Centre AVAILABILITY, LAUNCH OR MARKETING In phase III clinical trials. PATIENT GROUP BACKGROUND MCL is a rare form of non-Hodgkin lymphoma (NHL) affecting B lymphocytes in the lymph nodes4. The most common symptoms are one or more painless swellings in the neck armpit or groin, caused by enlarged lymph nodes5,6. Usually, more than one group of nodes is involved, and other areas of the body may also be affected, such as the bone marrow, bowel, stomach, liver or spleen5. Other systemic symptoms, known as B-cell symptoms, may occur in some people, including loss of appetite and weight loss, fatigue, night sweats and fevers5,6. MCL has an aggressive course with a pattern of resistant and relapsing disease, which typically renders it incurable with current standard pharmaceutical therapy7. NHS or GOVERNMENT PRIORITY AREA This topic is relevant to: Improving Outcomes: A Strategy for Cancer (2011). CLINICAL NEED and BURDEN OF DISEASE NHL is the sixth most common cancer in the UK8, with 10,875 new diagnoses in England and Wales in 20109. MCL accounts for around 3-10% of all NHLs (equating to around 326- 1,087 new diagnoses in England and Wales). Diagnosis peaks at around age 65, patients are predominantly male (male to female ratio of around 4:1)4 and the majority present with advanced disease6. The one- and five-year survival rates for MCL are 71% and 27%, respectively10. Around 50-70% of patients respond to treatment, however MCL typically progresses and the median survival is around 3 years11. In 2011-12, there were 178 hospital admissions for MCL (ICD-10: C83.1) in England, accounting for 182 finished consultant episodes and 395 bed days12, and in 2011, there were 236 deaths registered in England and Wales13. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance • NICE technology appraisal in development. Bendamustine in combination with rituximab for the first line treatment of mantle cell lymphoma (ID609). Expected date of issue to be confirmed14. • NICE technology appraisal. Rituximab for the first line treatment of stage III-IV follicular lymphoma: (review of NICE technology appraisal guidance 110) (TA243). January 201215. • NICE cancer service guidance. Improving outcomes in haemato-oncology cancer (CSGHO). October 200316. 3 NIHR Horizon Scanning Centre Other Guidance • McKay P, Leach M, Jackson R et al. Guidelines for the investigation and management of mantle cell lymphoma. 20127. • British Committee for Standards in Haematology. Best practice in lymphoma diagnosis and reporting. 201017. EXISTING COMPARATORS and TREATMENTS Treatment for MCL is dependent on stage, grade, performance status and whether or not patients are eligible for stem cell or bone marrow transplant6,7. There is no standardised treatment and entry into a clinical trial is recommended for eligible patients7,18. Current options include5,6,7,18: • Combination chemotherapy regimens ° R-CHOP – vincristine, doxorubicin, cyclophosphamide, prednisolone and rituximab ° FC-R – fludarabine, cyclophosphamide and rituximab ° FCM-R – fludarabine, cyclophosphamide, mitoxantrone and rituximab ° R-HCVAD – cytarabine, cyclophosphamide, doxorubicin, vincristine, dexamethasone and rituximab (for younger patients) ° R-maxi-CHOP/H Ara-C – vincristine, doxorubicin, cyclophosphamide, cytarabine, prednisolone and rituximab (for younger patients) ° Single chemotherapies may be offered – bendamustine, chlorambucil, cyclophosphamide, fludarabine (with or without rituximab) • Bone marrow or stem cell transplant (intensive chemotherapy in combination with stem cell transplant is considered standard of care in younger relapsed patients19 • Radiotherapy EFFICACY and SAFETY Trial SPRINT, NCT00875667, CC-5013-MCL- EMERGE, NCT00737529, CC-5013- 002; lenalidomide vs clinician’s choice of MCL-001; lenalidomide; phase II. single agent; phase II. Sponsor Celgene. Celgene. Status Ongoing. Ongoing. 20 Source of Trial registry2. Trial registry . information Location EU (incl UK), Israel, Russia. EU (incl UK), USA and other countries. Design Randomised, active-controlled. Single arm, uncontrolled. Participants n=254 (planned); aged ≥18 years; mantle n=134 (planned); aged ≥18 years; mantle cell lymphoma, refractory or relapsed up cell lymphoma; relapsed, refractory or to 3 times; progressive disease. progressive disease following treatment with bortezomib. Schedule Randomised to lenalidomide, oral, 10mga All participants receive lenalidomide, oral, or 25mgb, once daily for 21 days of 28 25mg, once daily for 21 days of 28 day day cycle; or clinician’s choice of single cycle. agentc. a Patients with creatinine clearance of ≥30mL/min but <60mL/min. b Patients with creatinine clearance of ≥60mL/min. c Chloramucil, rituximab, cytarabine, gemcitabine or fludarabine. 4 NIHR Horizon Scanning Centre Follow-up Active treatment until disease Not reported. progression; follow-up not reported. Primary Progression free survival. Tumour response; duration of response. outcome/s Secondary Overall response; duration of response; Safety; time to progression; OS. outcome/s tumour control rate; time to progression; time to treatment failure; time to tumour response; overall survival (OS); safety; quality of life. Expected Not reported. Not reported. reporting date ESTIMATED COST and IMPACT COST The cost of lenalidomide for MCL is not yet known. However, lenalidomide (Revlimid) is already marketed for the treatment of multiple myeloma; 25mg daily for 21 days of a 28 day cycle would cost £4,368 per cycle21. IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Reduced symptoms or disability Other: No impact identified Impact on Services Increased use of existing services Decreased use of existing services: oral treatment option. Re-organisation of existing services Need for new services Other: None identified Impact
Load more

Recommended publications
  • The Lymphoma and Multiple Myeloma Center
    The Lymphoma and Multiple Myeloma Center What Sets Us Apart We provide multidisciplinary • Experienced, nationally and internationally recognized physicians dedicated exclusively to treating patients with lymphoid treatment for optimal survival or plasma cell malignancies and quality of life for patients • Cellular therapies such as Chimeric Antigen T-Cell (CAR T) therapy for relapsed/refractory disease with all types and stages of • Specialized diagnostic laboratories—flow cytometry, cytogenetics, and molecular diagnostic facilities—focusing on the latest testing lymphoma, chronic lymphocytic that identifies patients with high-risk lymphoid malignancies or plasma cell dyscrasias, which require more aggresive treatment leukemia, multiple myeloma and • Novel targeted therapies or intensified regimens based on the other plasma cell disorders. cancer’s genetic and molecular profile • Transplant & Cellular Therapy program ranked among the top 10% nationally in patient outcomes for allogeneic transplant • Clinical trials that offer tomorrow’s treatments today www.roswellpark.org/partners-in-practice Partners In Practice medical information for physicians by physicians We want to give every patient their very best chance for cure, and that means choosing Roswell Park Pathology—Taking the best and Diagnosis to a New Level “ optimal front-line Lymphoma and myeloma are a diverse and heterogeneous group of treatment.” malignancies. Lymphoid malignancy classification currently includes nearly 60 different variants, each with distinct pathophysiology, clinical behavior, response to treatment and prognosis. Our diagnostic approach in hematopathology includes the comprehensive examination of lymph node, bone marrow, blood and other extranodal and extramedullary tissue samples, and integrates clinical and diagnostic information, using a complex array of diagnostics from the following support laboratories: • Bone marrow laboratory — Francisco J.
    [Show full text]
  • Low-Grade Non-Hodgkin Lymphoma Book
    Low-grade non-Hodgkin lymphoma Low-grade non-Hodgkin lymphoma Follicular lymphoma Mantle cell lymphoma Marginal zone lymphomas Lymphoplasmacytic lymphoma Waldenström’s macroglobulinaemia This book has been researched and written for you by Lymphoma Action, the only UK charity dedicated to people affected by lymphoma. We could not continue to support you, your clinical team and the wider lymphoma community, without the generous donations of our incredible supporters. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. To make a donation towards our work, please visit lymphoma-action.org.uk/Donate 2 Your lymphoma type and stage Your treatment Key contact Name: Role: Contact details: Job title/role Name and contact details GP Consultant haematologist/ oncologist Clinical nurse specialist or key worker Treatment centre 3 About this book Low-grade (or indolent) non-Hodgkin lymphoma is a type of blood cancer that develops from white blood cells called lymphocytes. It is a broad term that includes lots of different types of lymphoma. This book explains what low-grade non-Hodgkin lymphoma is and how it is diagnosed and treated. It includes tips on coping with treatment and dealing with day-to-day life. The book is split into chapters. You can dip in and out of it and read the sections that are relevant to you at any given time. Important and summary points are written in the chapter colour. Lists practical tips and chapter summaries. Gives space for questions and notes. Lists other resources you might find useful, some of which are online.
    [Show full text]
  • Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
    cancers Review Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy Miriam Marangon 1, Carlo Visco 2 , Anna Maria Barbui 3, Annalisa Chiappella 4, Alberto Fabbri 5, Simone Ferrero 6,7 , Sara Galimberti 8 , Stefano Luminari 9,10 , Gerardo Musuraca 11, Alessandro Re 12 , Vittorio Ruggero Zilioli 13 and Marco Ladetto 14,15,* 1 Department of Hematology, Azienda Sanitaria Universitaria Giuliano Isontina, 34129 Trieste, Italy; [email protected] 2 Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy; [email protected] 3 Hematology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy; [email protected] 4 Division of Hematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, 20133 Milan, Italy; [email protected] 5 Hematology Division, Department of Oncology, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] 6 Hematology Division, Department of Molecular Biotechnologies and Health Sciences, Università di Torino, 10126 Torino, Italy; [email protected] 7 Hematology 1, AOU Città della Salute e della Scienza di Torino, 10126 Torino, Italy 8 Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy; [email protected] 9 Hematology Unit, Azienda Unità Sanitaria Locale IRCCS di Reggio Emilia, 42123 Modena, Italy; [email protected] 10 Surgical, Medical and Dental Department of Morphological Sciences Related
    [Show full text]
  • Therapeutic Effect and Mechanism of Ibrutinib Combined with Dexametha- Sone on Multiple Myeloma
    ORIGINAL ARTICLES Hematology Department of The Second Hospital1, Cheeloo College of Medicine, Shandong University; Department of Hematology of Jining No. 1 People’s Hospital2; Institute of Biotherapy for Hematological Malignancies of Shandong University3; Shandong University-Karolinska Institute Collaborative Laboratory for Stem Cell Research4; Hematology Department of Linyi Central Hospital5; Hematology Department of Binzhou Medical University Hospital6; Institute of Medical Sciences, The Second Hospital, Cheeloo College of Medicine, Shandong University7, Jinan, Shandong, China Therapeutic effect and mechanism of ibrutinib combined with dexametha- sone on multiple myeloma SHENGLI LI1,2, LIKUN SUN1,3,4, QIAN ZHOU1,5, SHUO LI1,6, XIAOLI LIU1,3,4, JUAN XIAO1,3,4, YAQI XU1,3,4, FANG WANG7, YANG JIANG1,3,4,*, CHENGYUN ZHENG1,3,4 Received November 14, 2020, accepted December 2020 *Correspondence author: Yang Jiang, Hematology Department, the Second Hospital of Shandong University, 247th of Beiyuan Rd., Jinan, Shandong, China [email protected] Pharmazie 76: 92-96 (2021) doi: 10.1691/ph.2021.0917 Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase and has proven to be an effective agent for B-cell-mediated hematological malignancies, including multiple myeloma (MM). Several clinical trials of ibrutinib treatment combined with dexamethasone (DXMS) for relapsed MM have demonstrated high response rates, however, the mechanism still remains unclear. In this study, we explored the therapeutic effect and mechanism of ibrutinib combined with DXMS on MM in vitro and vivo. The apoptosis of MM cell lines and mononuclear cells from MM patients’ bone marrow induced by ibrutinib combined with DXMS was detected by flow cytometry and the expression of apoptosis-related proteins were detected by Western blot.
    [Show full text]
  • What Is Multiple Myeloma?
    cancer.org | 1.800.227.2345 About Multiple Myeloma Overview If you have been diagnosed with multiple myeloma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Multiple Myeloma? Research and Statistics See the latest estimates for new cases of multiple myeloma and deaths in the US and what research is currently being done. ● Key Statistics About Multiple Myeloma ● What’s New in Multiple Myeloma Research? What Is Multiple Myeloma? Cancer starts when cells begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 diseases. Lymphocytes (lymph cells) are one of the main types of white blood cells in the immune system and include T cells and B cells. Lymphocytes are in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies (also called immunoglobulins) that help the body attack and kill germs. Plasma cells, are found mainly in the bone marrow.
    [Show full text]
  • Mantle Cell Lymphoma (MCL)
    Mantle Cell Lymphoma (MCL) Page 1 of 9 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. PATHOLOGIC DIAGNOSIS INITIAL EVALUATION ESSENTIAL: ● Physical exam: attention to node-bearing areas, including Waldeyer's ring, ESSENTIAL: size of liver and spleen, and patient’s age ● Hematopathology review of all slides with at least one tumor paraffin block. ● Performance status (ECOG) Hematopathology confirmation of classic versus aggressive variant of MCL ● B symptoms (fever, drenching night sweats, unintentional weight loss) (blastoid/pleomorphic). Re-biopsy if consult material is non-diagnostic. ● CBC with differential, LDH, BUN, creatinine, albumin, AST, total bilirubin, 1 ● Adequate immunophenotype to confirm diagnosis alkaline phosphatase, serum calcium, uric acid ○ Paraffin panel: ● Screening for HIV 1 and 2, hepatitis B and C (HBcAb, HBaAg, HCVAb) - Pan B-cell marker (CD19, CD20, PAX5), CD3, CD5, CD10, and cyclin D1 ● Beta-2 microglobulin (B2M) - Ki-67 (proliferation rate) ● Chest x-ray, PA and lateral or ● Bone marrow bilateral biopsy with unilateral aspirate Induction ○ Flow cytometry immunophenotyping:
    [Show full text]
  • Divergent Clonal Evolution of a Common Precursor to Mantle Cell Lymphoma and Classic Hodgkin Lymphoma
    Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma Hammad Tashkandi1, Kseniya Petrova-Drus1, Connie Lee Batlevi2, Maria Arcila1, Mikhail Roshal1, Filiz Sen1, Jinjuan Yao1, Jeeyeon Baik1, Ashley Bilger2, Jessica Singh2, Stephanie de Frank2, Anita Kumar2, Ruth Aryeequaye1, Yanming Zhang1, Ahmet Dogan1, Wenbin Xiao1,* 1Department of Pathology, 2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY *Correspondence: Wenbin Xiao, MD, PhD Department of Pathology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065 [email protected] Running title: Clonally related mantle cell lymphoma and classic Hodgkin lymphoma Words: 1771 Figures: 2 Tables: 1 Reference: 14 Supplemental materials: Figure S1-S2, Table S1-S4 Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract: Clonal heterogeneity and evolution of mantle cell lymphoma (MCL) remain unclear despite the progress in our understanding of its biology. Here we report a 71 years old male patient with an aggressive MCL and depict the clonal evolution from initial diagnosis of typical MCL to relapsed blastoid MCL. During the course of disease, the patient was diagnosed with Classic Hodgkin lymphoma (CHL), and received CHL therapeutic regimen. Molecular analysis by next generation sequencing of both MCL and CHL demonstrated clonally related CHL with characteristic immunophenotype and PDL1/2 gains. Moreover, our data illustrate the clonal heterogeneity and acquisition of additional genetic aberrations including a rare fusion of SEC22B-NOTCH2 in the process of clonal evolution.
    [Show full text]
  • Lymphoproliferative Disorders
    Lymphoproliferative disorders Objectives: • To understand the general features of lymphoproliferative disorders (LPD) • To understand some benign causes of LPD such as infectious mononucleosis • To understand the general classification of malignant LPD Important. • To understand the clinicopathological features of chronic lymphoid leukemia Extra. • To understand the general features of the most common Notes (LPD) (Burkitt lymphoma, Follicular • lymphoma, multiple myeloma and Hodgkin lymphoma). Success is the result of perfection, hard work, learning Powellfrom failure, loyalty, and persistence. Colin References: Editing file 435 teamwork slides 6 girls & boys slides Do you have any suggestions? Please contact us! @haematology436 E-mail: [email protected] or simply use this form Definitions Lymphoma (20min) Lymphoproliferative disorders: Several clinical conditions in which lymphocytes are produced in excessive quantities (Lymphocytosis) increase in lymphocytes that are not normal Lymphoma: Malignant lymphoid mass involving the lymphoid tissues. (± other tissues e.g: skin, GIT, CNS ..) The main deference between Lymphoma & Leukemia is that the Lymphoma proliferate primarily in Lymphoid Tissue and cause Mass , While Leukemia proliferate mainly in BM& Peripheral blood Lymphoid leukemia: Malignant proliferation of lymphoid cells in Bone marrow and peripheral blood. (± other tissues e.g: lymph nodes, spleen, skin, GIT, CNS ..) BCL is an anti-apoptotic (prevent apoptosis) Lymphocytosis (causes) 1- Viral infection: 2- Some* bacterial
    [Show full text]
  • Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Version Date: 29JAN2019 Principal Investigator: Catherine J
    Protocol name: Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Version Date: 29JAN2019 Principal Investigator: Catherine J. Lee, MD Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Lead Org. ID: HCI98381/IRB# 98381 CTO#HCI-17-HEME-07 ClinicalTrials.gov ID – NCT03303950 Principal Investigator Catherine J. Lee, MD Blood & Marrow Transplant Program University of Utah 2000 Circle of Hope, Rm 2152 Salt Lake City, UT 84132 Phone: (801) 587-0231 Email: [email protected] Sub-investigator(s) Douglas Sborov, MD Clinical Instructor, Department of Medicine Phone: (801) 581-8394 Email: [email protected] Vedran Radojcic, MD Assistant Professor, Department of Medicine Phone: (801) 213-6109 Email: [email protected] Daniel R. Couriel, MD, MS Director, Blood & Marrow Transplant Program Professor, Department of Medicine Phone: (801) 587-4056 Email: [email protected] Jo-Anna Reems, PhD (Laboratory) Scientific Director, Cell Therapy & Regenerative Medicine Research Professor, Department of Medicine Phone: (801) 585-6262 Email: [email protected] Protocol name: Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Version Date: 29JAN2019 Principal Investigator: Catherine J. Lee, MD Michael Boyer, MD Associate Professor, Department of Medicine Phone: (801) 585-3229 Email: [email protected] Josef Prchal, MD Professor, Department of Medicine Phone: (801) 585-3229 Email: [email protected] Tibor Kovacsovics, MD Associate Professor,
    [Show full text]
  • Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
    Journal of Clinical Medicine Review Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions David A Bond 1,*, Peter Martin 2 and Kami J Maddocks 1 1 Division of Hematology, The Ohio State University, Columbus, OH 43210, USA; [email protected] 2 Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY 11021, USA; [email protected] * Correspondence: [email protected] Abstract: The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients effective treatment options, with increasing complexity in prioritization and se- quencing of these therapies. Chemo-immunotherapy remains widely used as frontline MCL treatment with multiple targeted therapies available for relapsed disease. The Bruton’s tyrosine kinase in- hibitors (BTKi) ibrutinib, acalabrutinib, and zanubrutinib achieve objective responses in the majority of patients as single agent therapy for relapsed MCL, but differ with regard to toxicity profile and dosing schedule. Lenalidomide and bortezomib are likewise approved for relapsed MCL and are active as monotherapy or in combination with other agents. Venetoclax has been used off-label for the treatment of relapsed and refractory MCL, however data are lacking regarding the efficacy of this approach particularly following BTKi treatment. Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies have emerged as highly effective therapy for relapsed MCL, with the CAR-T treatment brexucabtagene autoleucel now approved for relapsed MCL. In this review the authors summarize evidence to date for currently approved MCL treatments for relapsed disease including Citation: Bond, D.A; Martin, P.; sequencing of therapies, and discuss future directions including combination treatment strategies Maddocks, K.J Relapsed Mantle Cell and new therapies under investigation.
    [Show full text]
  • Mantle Cell Lymphoma
    Leukemia (1998) 12, 1281–1287 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu Mantle cell lymphoma: a retrospective study of 121 cases H Samaha1, C Dumontet1, N Ketterer1, I Moullet1, C Thieblemont1, F Bouafia1, E Callet-Bauchu2, P Felman2, F Berger3, G Salles1 and B Coiffier1 1Service d’He´matologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, and UPRES-JE 1879 ‘He´mopathies Lymphoides malignes’, Universite´ Claude Bernard, Pierre-Be´nite; 2Laboratoire d’He´matologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Be´nite; and 3Laboratoire d’Anatomie Pathologique, Hoˆpital Edouard-Herriot, Hospices Civils de Lyon, France Mantle cell lymphoma (MCL) patients represent a difficult prob- phoma usually begins as a disseminated disease with wide- lem, sometimes to establish the diagnosis but mostly because spread involvement of lymph nodes, spleen, bone marrow of their refractoriness to standard lymphoma treatments. Which treatments to apply and to whom is not yet defined. In this and other extranodal sites, specially the gastrointestinal tract study, we attempted to analyze the clinical features, to identify and Waldeyer ring. However, patients usually present a good the major prognostic factors, and to evaluate the outcome of performance status (PS) at diagnosis although adverse prog- 121 MCL patients treated in our institution between 1979 and nostic factors, such as high serum lactic dehydrogenase (LDH) 1997. Clinical data, treatment modalities, and International and ␤2-microglobulin levels, may be present. Initially, these Prognostic Index (IPI) score were evaluated. Median age was 63 patients usually respond to different types of therapy, but years.
    [Show full text]
  • Xgeva (Denosumab) Injection, for Subcutaneous Use Calcium and Vitamin D
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypocalcemia: Xgeva can cause severe symptomatic hypocalcemia, and These highlights do not include all the information needed to use fatal cases have been reported. Correct hypocalcemia prior to initiating XGEVA® safely and effectively. See full prescribing information for Xgeva. Monitor calcium levels during therapy, especially in the first XGEVA. weeks of initiating therapy, and adequately supplement all patients with Xgeva (denosumab) injection, for subcutaneous use calcium and vitamin D. (5.3) Initial U.S. Approval: 2010 • Osteonecrosis of the jaw (ONJ) has been reported in patients receiving Xgeva. Perform an oral examination prior to starting Xgeva. Monitor for symptoms. Avoid invasive dental procedures during treatment with ------------------------------RECENT MAJOR CHANGES-----------------------­ Xgeva. (5.4) Indications and Usage, Multiple Myeloma and Bone Metastasis from Solid • Atypical femoral fracture: Evaluate patients with thigh or groin pain to Tumors (1.1) 01/2018 rule out a femoral fracture. (5.5) Warnings and Precautions, Multiple Vertebral Fractures (MVF) Following • Hypercalcemia Following Treatment Discontinuation in Patients with Treatment Discontinuation (5.7) 01/2018 Growing Skeletons: Monitor patients for signs and symptoms of Warnings and Precautions, Embryo-Fetal Toxicity (5.8) 01/2018 hypercalcemia and treat appropriately. (5.6) • Multiple Vertebral Fractures (MVF) Following Treatment ---------------------------INDICATIONS AND USAGE---------------------------- Discontinuation: When Xgeva treatment is discontinued, evaluate the Xgeva is a RANK ligand (RANKL) inhibitor indicated for: individual patient’s risk for vertebral fractures. (5.7) • Prevention of skeletal-related events in patients with multiple myeloma • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of and in patients with bone metastases from solid tumors. (1.1) reproductive potential of potential risk to the fetus and to use effective • Treatment of adults and skeletally mature adolescents with giant cell contraception.
    [Show full text]